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Case Presentation
Mrs. C. is a 32-year-old femalediagnosed with melanoma and
metastasis to the liver. She has been
suffering from moderate, self-
described annoying pain in the
abdominal region almost constantly
for the past several weeks and self-
medicating with Ibuprofen, which
provides some relief. She also reports
episodes of nausea and difficulty
sleeping most nights. She arrives in
the late afternoon at a regional med-
ical research facility to enroll in a
clinical trial for experimental surgery
and chemotherapy in the morning.
She indicates to a staff nurse her
sense of concern and worry about
the impending surgery as well as her
prognosis. Upon arrival, the attend-
ing surgeon and anesthesiologist
approached her to obtain consent for
participation in the clinical trial. By
enrolling in the trial, she becomes eli-
gible for participation in several
other trials, including transfusion
related research and health related
quality of life (HRQOL) outcomes
assessment. Appointments through-
out the afternoon and early evening
and consuming at least several hours
of Mrs. C’s time consist of pre-
assessment lab work, a preoperative
history and physical, bowel prep,
and other activities related to the
various clinical trial protocols. Mrs.
C. verbalizes that she is physically
and emotionally exhausted from the
pace of the admission and enroll-
ment processes. That night she has
difficulty sleeping and develops a
severe migraine, making her eligible
for a clinical trial associated with
migraines. Over a period of several
hours, Mrs. C. gives informed con-
sent to participate in four different
clinical trials, each with differing
degrees of risk and associated bur-
den.
A
lthough the field of bioethics
has not clearly identified or
articulated the problem of
respondent burden in clinical trials,
the ethical concern that underlies the
concept has been acknowledged peri-
odically in health services research.
For example, health care providers
are sometimes reluctant to allow
clinical researchers to approach their
patients for inclusion in clinical trials
because they perceive the research to
be distressing or overly burdensome
for their patients.1 Clinicians’ desire
to diminish “burden” to symptom-
laden patients has also been identi-
fied as a factor that contributes to
recruitment barriers in palliative care
and end-of-life studies.2 This notion
of patient “distress” or “burden”
related to participation in clinical
research is comparable to what
social scientists and survey method-
ologists have previously identified as
“respondent burden.” This phenom-
enon also needs to be addressed in
the area of clinical research.
The Office of Management and
Budget (OMB) used the term respon-
dent burden when it introduced
efforts to reduce the number and fre-
quency of federal requests for infor-
mation and to minimize both the
time and effort required of survey
respondents in order to maximize
response rates or research participa-
tion.3 Bradburn further explicated
this concept in health survey
research, where he defined it as a
subjective phenomenon that may be
related to four differing factors:
interview length; effort requirement
on the part of the respondent; the
sensitivity of the questions being
asked and the stress they may engen-
der; and the frequency of participat-
ing in interviews.4 Yet to date, no
one has directly addressed the issue
of respondent burden in cases in
which the subject population is seri-
ously ill, the subject’s participation is
requested in multiple, ongoing stud-
ies, and where the research is clini-
cally based, rather than limited to
survey participation. Given the
nature of human subjects research in
clinical medicine, there is an obvious,
pressing need to explore the issue of
respondent burden, to understand its
frequency and severity, and to create
safeguards to minimize it. 
Following Bradburn, we define
respondent burden in the clinical
research context as a subjective phe-
nomenon that describes the percep-
tion by the subject of the psychologi-
cal, physical, and/or economic hard-
ships associated with participation in
the research process. Respondent
burden may vary in intensity and
degree, depending upon the risk level
of the research, the procedures that
the research entails, and the individ-
ual subject’s condition, prognosis,
Respondent Burden in Clinical Research:
When Are We Asking Too Much of Subjects?
BY CONNIE M. ULRICH, GWENYTH R. WALLEN, AUTUMN FEISTER, AND CHRISTINE GRADY
Connie M. Ulrich, Gwenyth R. Wallen, Autumn
Feister, and Christine Grady, “Respondent Burden in
Clinical Research: When Are We Asking Too Much
of Subjects?” IRB: Ethics & Human Research 27
No. 4 (2005): 17-20.
JU LY-AU G U ST 2005 IRB:  ET H I C S & HU M A N RE S E A RC H
18
mental state, and support systems.
Returning to our case, the potential
for respondent burden is easy to
identify: Mrs. C., who is already suf-
fering from pain and symptoms
related to her disease, may be partic-
ularly burdened by being asked to
commit limited physical and emo-
tional energy to the demands of par-
ticipating in multiple studies and
clinical trials.
The Clinical Context
Clinical researchers face similarissues to those of social scientists
and survey methodologists when
considering respondent burden,
including sample selection, method-
ological approaches, and the
time/energy commitment required of
their participants. Yet, they also face
additional challenges unique to the
nature of their research. First, clini-
cal research subjects are likely to be
patients with an illness, which means
they are already burdened with the
physical, psychological, and social
challenges associated with their ill-
ness. Clinical research subjects may
choose to participate in research for
the explicit benefit and/or betterment
of their immediate health, their fami-
lies’ potential future health, and/or
to advance the state of the science.
Like other research subjects, they
commit valuable time and effort to
participate in research, but at signifi-
cantly increased cost given their vul-
nerability and compromised health
status.
Given the competitive nature of
the research environment, the num-
ber of related clinical trials, and the
ever-increasing pressure upon investi-
gators to recruit and retain research
subjects to meet enrollment goals, it
is not surprising that many individu-
als will be recruited to enroll in more
than one clinical trial. Consequently,
some individuals will end up partici-
pating in trials that are being con-
ducted concurrently, resulting in
varying degrees of intrusion and
intensity.5 As illustrated by the case
study, the concern for respondent
burden is not solely related to the
burden of participation in one study,
(although such participation may be
demanding for seriously ill individu-
als such as Mrs. C), but rather about
the aggregate burden of participation
in multiple studies. Even if each indi-
vidual study is designed well and
might generate valuable and general-
izable knowledge, subjects may
become physically exhausted, psy-
chologically distressed, and/or eco-
nomically burdened. Little is known,
however, from the subjects them-
selves about what they perceive to be
burdensome in research.6 Thus, clini-
cians and researchers should ask
themselves, “When are we asking
too much of subjects in the course of
clinical research?” While it is safe to
assume that there is such a phenome-
non as respondent burden in clinical
research, we do not currently know
how widespread the phenomenon is,
what types of circumstances are
most likely to engender it, and what
types of responses are necessary to
address it. We need empirical data to
answer these pressing questions.
Once there is better understand-
ing of the phenomenon of respon-
dent burden, questions remain about
who should define respondent bur-
den and what guidelines should be
followed to minimize the problem.
Should seriously ill individuals
recruited to participate in a clinical
trial determined by an Institutional
Review Board (IRB) to be greater
than minimal risk and procedurally
burdensome be prohibited from con-
current participation in any other
type of research? How much differ-
ence should the subject’s clinical sta-
tus, the burdens of additional stud-
ies, or the interests of the subject
make in determining whether con-
current enrollment is appropriate?
Who should make this determina-
tion—the IRB, the patient, the inves-
tigator, or someone else?
In the absence of guidelines and
professional consensus about what
constitutes too much respondent
burden, IRBs might be the appropri-
ate body to make such a determina-
tion. However, investigators and
patient-subjects might also be appro-
priate judges in determining whether
clinical trial participation reflects
patient-subject values, goals, and pri-
orities. Given the lack of empirical
data, conceptual clarity, and ethical
discourse on what constitutes
respondent burden, we are limited in
our ability to answer these questions. 
Reducing Burden
Several strategies for reducing bur-den in clinical research may
include integrating multiple ancillary
studies into one package for the IRB
to review rather than limiting the
number of research protocols in
which subjects can concurrently
enroll; periodically revisiting consent
for patients involved in multiple
studies;7 establishing and reviewing a
central registry of studies; and using
research participant advocates.
 Integrating Multiple
Ancillary Studies. One possible
strategy for reducing respondent bur-
den would be to integrate multiple
ancillary studies into one package for
the IRB to review and potential sub-
jects to consider rather than limiting
the number of clinical trials in which
individuals can concurrently enroll.
This would be important for two
reasons. First, restricting concurrent
participation may be objectionable
because this option would not only
potentially violate an individual’s
right to choose research studies that
are consonant with her values and
goals but also hamper recruitment
targets and possibly the validity of
data derived from underpowered tri-
als.8 Second, demands on IRB mem-
bers to accomplish protective over-
sight of human subjects and to
ensure compliance with institutional
and other research rules and regula-
tions continue to increase in number,
scope, and complexity. More often
than not, these demands must be
met with limited resources.9 Thus,
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integrating studies may help IRBs
balance the demands of efficiency in
protocol review with ethical over-
sight of human subjects.
 Revisiting Consent. Clinical
scientists have begun to examine the
importance of addressing each indi-
vidual’s unique experience as a par-
ticipant in clinical trials, particularly
the experience of critically ill and ter-
minally ill patient-subjects. When
individuals are faced with personal
crises, we assume they will need to
conserve their inner or external
resources. At these times, they
deserve to be self-protective, self-
concerned, and self-focused; others
should be supporting them and not
requesting their help. Yet, some
patients may only find satisfaction
and meaning during trying times
through the knowledge that they are
helping others. Limiting their ability
to participate in research could ulti-
mately inhibit their ability to care for
themselves.
In a recent survey by Burnet and
colleagues of breast cancer patients’
views on enrollment in clinical trials,
the majority of respondents said they
would consider enrolling in more
than one study if the study were ade-
quately explained to them.10 More
than half of the respondents ques-
tioned 6-12 months following com-
pletion of their primary treatment
said there should be no limit on the
number of clinical studies offered to
patients. However, the survey did
not ask individuals about the type of
research they would consider join-
ing. Respondents’ concerns about
participation in multiple studies
included demands on their personal
time, transportation issues, and
attending to one’s normal life
processes.
More studies of this kind would
help determine subjects’ perception
of burdens and under what circum-
stances it is appropriate to approach
similarly situated ill subjects for
enrollment in additional research.
Some subjects, for example, may
welcome participation in an addi-
tional study, particularly if the
research questions are pertinent or
salient in some way to their life. For
example, subjects enrolled in a Phase
I clinical trial that involves an inva-
sive surgical intervention may find
the opportunity to discuss their asso-
ciated tumor or surgical pain—as it
pertains to an additional clinical
trial—important and potentially
cathartic, psychologically beneficial,
and contributing to the well-being of
future patients. Moreover, subjects
may view additional studies as inter-
related rather than separate. It may
be important to distinguish when
respondents say “yes” to additional
research fully understanding what
the additional research will mean in
terms of associated risk(s), benefits,
and added respondent burden, from
when they simply find it difficult to
say “no” in some situations. With
each additional study they enroll in,
the aggregate burden may be greater
on the individual. In cases where
research subjects appear ambivalent
and are hesitant to say “no” to addi-
tional research, Wendler and
Rackoff suggest that researchers con-
duct an independent assessment of
subjects’ willingness to participate
and reaffirm their right to
withdraw.11
 Central Registration. A third
possible strategy is to establish a cen-
tral registry of every clinical study
and research subject. IRBs could use
the registry to periodically conduct a
targeted form of research protocol
review for those studies where bur-
den and unnecessary duplication
may be implicated.12 Levine and col-
leagues propose “special scrutiny”
for protocols they describe as “out-
liers,” i.e., research that involves
innovative translational research and
risk of significant harm or death to
subjects, and research that raises
serious ethical questions for which
there is no consensus about whether
it should go forward. Research
involving respondent burden as we
define it could also fall under the
“special scrutiny” umbrella.
Different levels of review or the use
of an independent research monitor
could be used for clinical trials that
involve greater than minimal risk
and that are procedurally burden-
some to research subjects.
 Research Participant
Advocates. Finally, advocates in
clinical research settings could be
used to help research participants
better understand research studies
offered to them, to monitor the
amount of burden individual partici-
pants are experiencing, and to help
research participants negotiate deci-
sionmaking, including the decision
to decline to participate in studies
that are perceived as too burden-
some.13
Future Research Needs
Research is needed to determinehow frequently seriously ill indi-
viduals participate in multiple clini-
cal trials, and the extent to which
respondent burden varies by the sub-
ject’s disease severity, the type of
research they enroll in (qualitative
versus quantitative, experimental
versus nonexperimental), the number
of studies in which they are enrolled,
and the prospect of financial com-
pensation for enrollment. Studies
that identify the extent to which peo-
ple feel free to decline research par-
ticipation, especially when they are
patients of the clinician-researcher or
of her colleagues in the same institu-
tion, are also needed. So too are
studies that examine what subjects,
IRBs, and investigators perceive as
burdensome, what factors and/or
characteristics might minimize, miti-
gate, and/or intensify respondent
burden in clinical research, and that
explore the extent to which partici-
pants perceive interviews or quality
of life assessments as more beneficial
than burdensome. Understanding
research subjects’ perception of
respondent burden—whether the
burden is psychological, physical,
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